Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers

Código QR

Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers

Jan A Stratmann, Martin SebastianDepartment of Internal Medicine II, University Clinic of Frankfurt, 60596 Frankfurt, GermanyAbstract: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide. Due to often unspecific disease symptoms, locally advanced or metastatic disease i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stratmann JA, Sebastian M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	non-small cell lung cancer polo-like kinase targeted therapy therapy resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/de8eaf3055364c7d9ff3222bea2226f1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Recent Progress in Development of Polo-Like Kinase 1 Inhibitors: Efforts So Far
por: Ramesh L. Sawant, et al.
Publicado: (2021)

Silybum marianum seed disrupts mitosis by reducing polo-like kinase 1 in breast cancer cells
por: Hsing-Yu Jao, et al.
Publicado: (2022)

Targeting AXL in NSCLC
por: Zaman A, et al.
Publicado: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen M, et al.
Publicado: (2018)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
por: Liesbeth M. Hondelink, MD, et al.
Publicado: (2021)

Adjuvant targeted therapy for non-small cell lung cancer
por: Konstantin K. Laktionov, et al.
Publicado: (2020)

Prospects for the development of adjuvant therapy for non-small cell lung cancer
por: K. K. Laktionov, et al.
Publicado: (2020)

Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
por: Boning Cai, et al.
Publicado: (2021)

Technical Feasibility and Safety of Repeated Computed Tomography–Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC
por: Puja Shahrouki, MD, et al.
Publicado: (2021)

HER2 Amplification in Advanced NSCLC Patients After Progression on EGFR-TKI and Clinical Response to EGFR-TKI Plus Pyrotinib Combination Therapy
por: Gan J, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors in Adult Glioblastoma: An (Un)Closed Chapter?
por: Paula Aldaz, et al.
Publicado: (2021)

Clinical utility of liquid biopsy for the diagnosis and monitoring of EML4-ALK NSCLC patients
por: Sánchez-Herrero Estela, et al.
Publicado: (2020)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows SM, et al.
Publicado: (2019)

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
por: Tan AC, et al.
Publicado: (2021)

Successful treatment of locally advanced lung cancer using late concurrent chemoradiation therapy administered after immune checkpoint inhibitor plus platinum chemotherapy
por: Taichi Matsubara, et al.
Publicado: (2021)

Adaptive Radiation Therapy in the Treatment of Lung Cancer: An Overview of the Current State of the Field
por: Huzaifa Piperdi, et al.
Publicado: (2021)

Involvement of endothelial CK2 in the radiation induced perivascular resistant niche (PVRN) and the induction of radioresistance for non-small cell lung cancer (NSCLC) cells
por: Li,Qianwen, et al.
Publicado: (2019)

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
por: Michela Verzè, et al.
Publicado: (2021)

Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
por: Raj Kumar Mongre, et al.
Publicado: (2021)

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
por: Tian Tian, et al.
Publicado: (2021)

HSP90 as a novel molecular target in non-small-cell lung cancer
por: Esfahani K, et al.
Publicado: (2016)

A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
por: Lee CS, et al.
Publicado: (2020)

The Ki-67 Proliferation Index-Related Nomogram to Predict the Response of First-Line Tyrosine Kinase Inhibitors or Chemotherapy in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor-Mutant Status
por: Weiguo Gu, et al.
Publicado: (2021)

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
por: Whitney E. Lewis, PharmD, et al.
Publicado: (2021)

Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
por: ZHU Kuikui, et al.
Publicado: (2021)

Immunotherapeutic Advances for NSCLC
por: Massafra M, et al.
Publicado: (2021)

Novel Multimodal Management of Post-Partum Synchronous Metastatic Pulmonary EBV-Associated Lymphoepithelioma-Like Carcinoma (LELC)—A Case Report
por: Montserrat Pazos, et al.
Publicado: (2021)

PPy@Fe3O4 Nanoparticles Inhibit Tumor Growth and Metastasis Through Chemodynamic and Photothermal Therapy in Non-small Cell Lung Cancer
por: Danruo Fang, et al.
Publicado: (2021)

Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis
por: Ling Peng, et al.
Publicado: (2021)

Targeted Therapies in Cancer: To Be or Not to Be, Selective
por: Skye Montoya, et al.
Publicado: (2021)

Overcoming PLK1 inhibitor resistance by targeting mevalonate pathway to impair AXL-TWIST axis in colorectal cancer
por: Sonia Solanes-Casado, et al.
Publicado: (2021)

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
por: Maja Šutić, et al.
Publicado: (2021)

High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma
por: Laura Kohtamäki, et al.
Publicado: (2022)

Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy
por: Łukasz Trembecki, et al.
Publicado: (2021)

Safety of Surgery after Neoadjuvant Targeted Therapies in Non-Small Cell Lung Cancer: A Narrative Review
por: Tomasz Marjanski, et al.
Publicado: (2021)

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
por: Facchinetti F, et al.
Publicado: (2019)

Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions
por: Maliha Khan, et al.
Publicado: (2021)

Molecular targets in GI malignancies – A pathologist's perspective
por: Satyajit Pawar, et al.
Publicado: (2021)

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
por: Gadgeel S, et al.
Publicado: (2019)

Comparison of the efficacy of first-line therapy with different generations of EGFR tyrosine kinase inhibitors in patients with advanced EGFR-associated non-small cell lung cancer: a network meta-analysis of overall survival data
por: Alexey A. Bogdanov, et al.
Publicado: (2021)